Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Ratios

Vanda Pharmaceuticals (VNDA) Long-Term Investments (2019)

Vanda Pharmaceuticals' Long-Term Investments history spans 2 years, with the latest figure at $61.8 million for Q3 2019.

On a quarterly basis, Long-Term Investments changed N/A to $61.8 million in Q3 2019 year-over-year; TTM through Sep 2019 was $61.8 million, a N/A change, with the full-year FY2011 number at $19.0 million, changed N/A from a year prior.
Long-Term Investments hit $61.8 million in Q3 2019 for Vanda Pharmaceuticals, up from $12.5 million in the prior quarter.
Over the last five years, Long-Term Investments for VNDA hit a ceiling of $61.8 million in Q3 2019 and a floor of $12.5 million in Q2 2019.